Enstilar® Foam in the Treatment of Chronic Plaque Psoriasis in Patients With Skin of Color

Summary

This will be a single-center, randomized, double-blinded, vehicle-controlled clinical study to determine the efficacy of Enstilar® foam, a combination of calcipotriene and betamethasone dipropionate 0.005%/0.064%, in the treatment of psoriasis vulgaris in skin of color (FST IV-VI). This study will also evaluate the degree of erythema versus hyperpigmentation in psoriasis plaques in skin of color (and its change with Enstilar ® treatment) as well as the effect of Enstilar ® on post-inflammatory hyperpigmentation and quality of life.

Timeline

Start

2018-05-21

Primary completion

2019-09-25

Completion

2019-09-25

Drugs

Indications